Differences in perspective on basic research studies versus large-scale, guideline-compliant studies evaluating the potential developmental/reproductive effects of bisphenol A (BPA) reported by Myers et al. (2009) reflect disagreement in and ignorance of the roles and strengths and weaknesses of these study types. This controversy affects BPA safety assessment, which has become a major public policy issue. In this article I review characteristics and uses of basic/exploratory research versus regulatory guideline-compliant studies, using BPA as a case study.

Background
==========

Basic/exploratory research in toxicology is conducted to identify unknown potential hazards, elucidate the mode/mechanism of action for known toxicants, or explore novel end points for possible subsequent formal validation. These studies commonly employ routes of administration and/or doses that are not relevant for humans; include few dose groups and few animals per group, and/or nonvalidated end points; are not tracked to adverse outcomes; and are typically creative, short term, relatively inexpensive, and funded by universities, government grants, and nongovernmental organizations (NGOs). These basic research studies play significant roles but are limited in assessing potential risks to human health. To assess risks, governmental agencies rely on guideline-compliant studies using appropriate exposures (routes, doses, durations), validated end points linked to adverse outcomes, and appropriate group sizes and numbers. Exploratory research and risk assessment studies are interactive and iterative ([@b48-ehp-117-1644]).

Risk-relevant studies are performed under regulatory testing guideline (TG) protocols and Good Laboratory Practices (GLPs). The Food and Drug Administration ([@b19-ehp-117-1644]) established standards for design, conduct, and reporting of nonclinical laboratory studies in support of applications for FDA marketing permits. The U.S. Environmental Protection Agency (EPA) prescribed GLP standards for studies on health and environmental effects and chemical fate testing under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA; [@b82-ehp-117-1644]) and under the Toxic Substances Control Act (TSCA; [@b84-ehp-117-1644]). The Organisation for Economic Co-operation and Development (OECD) has also established GLPs ([@b53-ehp-117-1644]). The U.S. EPA may consider data not developed in accordance with these provisions "insufficient to evaluate the health effects, environmental effects, and fate of the chemical." ([@b83-ehp-117-1644]).

Guideline-compliant studies evaluate potential hazard and risk of substances and are performed following/exceeding governmental TGs and GLPs. Guideline-compliant multi-generational reproductive toxicity studies, with large numbers of animals per group per generation, are very expensive and typically funded by manufacturers, consortia of manufacturers, and/or governments. These studies are necessary for hazard evaluation and/or risk assessment because of their statistical power to detect reproducible effects linked to adverse outcomes; relevant exposure routes, doses, and animal models; and dose--response assessment. GLPs require complete, permanent documentation of staff; valid study design; standard operating procedures (SOPs); training, performance, formulation, and statistical analyses; and retention of summary/individual data, so there is confidence in the study design, performance, and results, and anyone can subsequently fully reconstruct the study.

Harmonization of TGs by the OECD \[United States (U.S. EPA), Japan, and Europe\] for industrial chemicals, and by the International Conference on Harmonization (European Commission, Japanese Ministry, U.S. FDA, and pharmaceutical manufacturers) for pharmaceuticals, ensures guidelines are globally consistent and acceptable. Development and revision of governmental regulatory guidelines involve experts from government, academia, and industry evaluating the strengths and weaknesses of the current and proposed TGs and end points. For the revised two-generation study TGs, new validated end points include anogenital distance (AGD), retained nipples/areolae, acquisition of puberty, estrous cyclicity, andrology, and ovarian primordial follicle counts. Proposed guidelines (and/or new end points) are published for comment (e.g., [@b85-ehp-117-1644]). After comments and revisions, the final guideline is published \[U.S. EPA TSCA new two-generation guideline ([@b86-ehp-117-1644]); U.S. EPA Office of Prevention, Pesticides, and Toxic Substances (OPPTS; including TSCA and FIFRA) version 1998; and the new OECD version ([@b54-ehp-117-1644])\]. TGs evolve over time, and appropriate changes are incorporated as described above. If/when researchers identify new end points for inclusion, there is a defined process to follow. Virtually all new validated end points in current guidelines originated in exploratory research.

When a government guideline is developed for a "new" study type, such as the rat ovariectomized uterotrophic and castrate Hershberger assays for endocrine disruptors, a laboratory evaluates the protocol's variables, and governmental, industrial, and contract testing laboratories run the protocol with known (and coded) chemicals. A background review document with laboratory results and a draft guideline are published. The process involves scientists, testing laboratories, governmental oversight, and peer review before the guideline and/or end point(s) is officially acceptable. Although TGs are comprehensive and provide a robust baseline standard, one can also add evaluations to enhance the ability of the guideline to detect adverse effects.

Guideline studies are required for governmental risk assessment and critical for risk evaluations by other agencies, such as the National Toxicology Program ([@b52-ehp-117-1644]), the Center for the Evaluation of Risks to Human Reproduction ([@b11-ehp-117-1644]), and the European Food Safety Authority ([@b16-ehp-117-1644]). Guideline studies can inform further exploratory research and are universally considered robust, reliable, and essential to confirm, refute, and/or expand exploratory studies. When appropriate, nonvalidated end points can be used in formal risk assessments as "points of departure," but only when the end point is known to relate directly to an adverse outcome; for example, fetal testicular testosterone content was used as the point of departure for a U.S. EPA phthalate risk assessment because the direct adverse consequences from low fetal testosterone were known.

BPA is a high-production-volume chemical. Ubiquitous human exposure to very low BPA doses occurs primarily through consumption of food that comes in contact with materials containing BPA, such as polycarbonate plastics and epoxy resins (manufactured from BPA) used in plastic bottles, and food/beverage container coatings ([@b16-ehp-117-1644]). There is considerable debate on whether low oral BPA doses cause reproductive/developmental effects in animals. Guideline-compliant BPA studies have shown effects only at high doses, which also caused parental systemic toxicity, but have not reproduced the low-dose effects reported in exploratory BPA studies.

Myers et al. (2009) criticized GLP-compliant studies for serious conceptual and methodologic flaws, failure to address replication, and using methods not sensitive or "state of the art" and opined that these studies cannot detect effects of low-dose BPA. They specifically criticized our BPA \[and 17β-estradiol (E~2~)\] dietary studies ([@b81-ehp-117-1644], [@b78-ehp-117-1644], [@b79-ehp-117-1644], [@b80-ehp-117-1644]).

Guideline-Compliant BPA Studies
===============================

Our three-generation reproductive toxicity study of dietary BPA in CD(SD) rats (under OPPTS guideline 870.03800; [@b87-ehp-117-1644]) included six BPA dose groups (30/sex/group/generation) at 0.015--7,500 ppm (\~ 0.001--500 mg/kg/day) ([@b81-ehp-117-1644]). We found no nonmonotonic dose--response patterns or effects on any parameters in the low-dose region (1 μg/kg/day to 5 mg/kg/day). We reported reduced adult body and organ weights at ≥ 50 mg/kg/day and renal and hepatic histopathology at 500 mg/kg/day. Reproductive/developmental toxicity was present only at 500 mg/kg/day in the presence of overt adult systemic toxicity. At doses \< 500 mg/kg/day, we found no BPA effects on prostate weights (lobe or whole gland), acquisition of puberty, or other reproductive organ weights or histopathology in adult offspring. The systemic no observable adverse effect level (NOAEL) was 5 mg/kg/day, and the reproductive/developmental NOAEL was 50 mg/kg/day. BPA was not considered a rat selective reproductive/developmental toxicant.

[@b18-ehp-117-1644], funded by the Japanese Ministry of Health and Welfare, published a two-generation BPA rat study, with daily gavage dosages of 0 and 0.2--200 μg/kg/day under U.S. EPA GLPs and OPPTS TG ([@b87-ehp-117-1644]), adding endocrine-sensitive and neurobehavioral end points. They found no significant, compound-related effects in any parameter at any dose, consistent with our conclusions.

Myers et al. (2009) criticized our rat study for the absence of a positive control, although we reported successful use of 2.5 ppm dietary E~2~ (\~ 180--200 μg/kg/day) in another dietary multigenerational study using the same rat source ([@b77-ehp-117-1644]). [@b8-ehp-117-1644], using a 90-day plus one-generation study design, evaluated dietary E~2~ in CD(SD) rats; determined that dietary concentrations of 10 and 50 ppm were incompatible with pregnancy or offspring, and found the same effects at 2.5 ppm as we did. A "positive control" group is neither required nor routinely employed in guideline-compliant studies, because the study design and end points are validated (i.e., known to result in adverse consequences from an appropriate chemical by appropriate routes and doses). Neurotoxicity guideline protocols require annual evaluation of the test system with positive controls.

Because rats were cited as insensitive (or less sensitive than mice) to estrogens, mouse BPA reproductive toxicity studies were requested by European regulatory agencies. Our laboratory performed one- and two-generation reproductive toxicity studies of dietary E~2~ in CD-1 mice ([@b78-ehp-117-1644], [@b79-ehp-117-1644]) under OECD guidelines and GLPs, to establish appropriate end points and effects at low to high doses of an endogenous estrogen and to determine the appropriate dietary E~2~ positive control concentration/dose for the subsequent dietary BPA study in CD-1 mice. We evaluated dietary E~2~ concentrations from 0.001 to 50 ppm (\~ 0.2 μg/kg/day to \~ 8 mg/kg/day). Doses ≥ 400 μg/kg/day (≥ 2.5 ppm) resulted in normal F~0~ mating behavior but no pregnancies or F~1~ offspring ([@b78-ehp-117-1644]). Doses of \~ 0.2--80 μg/kg/day E~2~ (0.001--0.5 ppm) resulted in appropriate reproductive functions over one and two adult/offspring generations ([@b78-ehp-117-1644], [@b79-ehp-117-1644]), with anticipated dose-related effects on acquisition of puberty \[accelerated vaginal patency (VP), delayed preputial separation\] and AGD (shortened in males); these doses also affected weights of ovaries, uterus, cervix, and vagina, but not prostate and nonmonotonic dose--response curves for any parameter. The most complete spectrum of E~2~-dependent effects occurred at 0.5 ppm in the E~2~ two-generation study ([@b79-ehp-117-1644]), such that E~2~ concentration (\~ 80--120 μg/kg/day) was the positive control for the mouse dietary BPA study.

The mouse study ([@b80-ehp-117-1644]), under OECD GLPs and guidelines, involved two vehicle control groups (0 ppm), six dietary BPA dose groups (0.018--3,500 ppm; 0.003--600 mg/kg/day), and one positive control group (E~2~), with 28 mice/sex/group/generation over two parental and off-spring generations. One additional postwean F~1~ male/litter was retained through adult necropsy and histopathology. E~2~ results confirmed sensitivity of CD-1 mice to estrogen. We found no BPA-related effects on mating, fertility, or gestational indices or on ovarian primordial follicle counts, estrous cyclicity, precoital interval, neonatal offspring AGD, sex ratios, survival, andrology, reproductive organ weights, or histopathology (including testes and prostate). Adult systemic effects at 300 ppm (\~ 50 mg/kg/day) included only liver histopathology; at 3,500 ppm (\~ 600 mg/kg/day), there were reduced body weights, increased renal and liver weights, and histopathology in adult males, and transient effects on weanling body and organ weights, but no adverse effects on adult reproductive structures or functions. These transient effects were considered secondary to systemic toxicity. At lower doses (0.018--30 ppm; \~ 0.003--5 mg/kg/day), there were no treatment-related effects or nonmonotonic dose--response curves for any parameter at any dose. The systemic NOAEL was 30 ppm BPA (\~ 5 mg/kg/day), and the reproductive/developmental NOAEL was 300 ppm (\~ 50 mg/kg/day). BPA was not considered a selective mouse reproductive or developmental toxicant ([@b80-ehp-117-1644]). We identified the same BPA systemic and reproductive/developmental NOAELs (and sensitivity comparable to similar dietary E~2~ intakes) in rats and mice, with no BPA effects on the prostate weight or histopathology. Strain differences in response to estrogens in rats (and mice) vary across tissues, so no strain can be considered more sensitive than another ([@b29-ehp-117-1644]). E~2~ activities via estrogen receptor-α in the reproductive tract did not display major strain differences in OECD multilaboratory rat uterotrophic assay validation studies; oral BPA was only a weak partial agonist at 400--600 mg/kg/day ([@b37-ehp-117-1644]).

Pharmacokinetics of BPA
=======================

The lack of low-dose effects in oral studies is consistent with BPA pharmacokinetics. Absorption, distribution, metabolism, and elimination (ADME) and any subsequent BPA toxicity depend on route of administration. Oral BPA at low (or high) doses is almost completely (\> 95%) monoglucuronidated by the intestine and/or liver before it enters general circulation ([@b33-ehp-117-1644], [@b34-ehp-117-1644]; [@b57-ehp-117-1644]). BPA monoglucuronide (BPA-G) is inactive as an estrogen ([@b42-ehp-117-1644]; [@b69-ehp-117-1644]) and is rapidly and almost completely excreted by urine and feces in rats ([@b57-ehp-117-1644]) and by urine in humans ([@b13-ehp-117-1644]; [@b88-ehp-117-1644]), with a half-life of approximately 4 hr. Although neonatal rats and human infants have less glucuronidation enzymes than adults, [@b14-ehp-117-1644] reported that ≥ 99% of oral 1 mg/kg BPA (333- to 1,000-fold higher than human perinatal or adult exposures) in neonatal rats was glucuronidated. [@b10-ehp-117-1644] confirmed infant BPA metabolism, reporting that \> 90% BPA in urine from premature babies was present as BPA-G. There is much higher (and longer) bioavailability of parent BPA from non-oral routes of administration ([@b57-ehp-117-1644]).

Exploratory Research BPA Studies
================================

Exploratory research studies evaluate early, molecular, nonvalidated end points but rarely follow these initial responses to long-term adverse consequences. If the study is well conducted and reproducible and the interpretation is clear, it can be used to support risk assessment. vom Saal's laboratory ([@b47-ehp-117-1644]) reported enlarged prostates in F~1~ adult CF-1 mouse offspring (six or seven males per group) from *in utero* exposure on gestational days (GDs) 11--17 to oral BPA at 2 and 20 μg/kg/day. These effects on offspring prostate weights (no histopathology was performed) triggered robust evaluations by [@b9-ehp-117-1644] and [@b5-ehp-117-1644], who could not replicate Nagel et al.'s prostate findings. The studies by Cagen et al. and Ashby et al. were criticized for no response to 0.2 μg/kg body weight/day diethylstilbestrol (DES) as a "positive control," which was recommended to the authors by vom Saal; however, oral, low-dose DES prostate effects reported by [@b90-ehp-117-1644] have never been replicated. Other small mouse studies reported low-dose BPA effects on fetal prostate morphometry ([@b76-ehp-117-1644]), acceleration of puberty (not on VP but timing of first estrus relative to VP; [@b30-ehp-117-1644]), altered mammary gland development (non-oral BPA exposure; [@b41-ehp-117-1644]; [@b45-ehp-117-1644]), and altered mouse behavior (oral BPA; [@b62-ehp-117-1644]). These findings, not replicated by robust studies in CF-1 mice ([@b9-ehp-117-1644]) or guideline-compliant studies in CD-1 mice ([@b80-ehp-117-1644]), likely prompted the CERHR (2007) to indicate "some concern" for BPA's neurobehavioral effects and "minimal concern" for accelerated puberty and prostate weights. The NTP prepared its own BPA report ([@b52-ehp-117-1644]), expressing "minimal concern" for effects on mammary gland development and accelerated puberty, and "some concern" for neurobehavioral and prostate gland effects.

Responses to Specific Criticisms by Myers et al. (2009)
=======================================================

Myers et al. (2009) criticized the GLP-compliant studies for serious conceptual and methodologic flaws, failure to replicate, and methods not sensitive or "state of the art." They argued that industry-sponsored GLP studies cannot detect low-dose effects and attacked the BPA studies in CD(SD) rats ([@b81-ehp-117-1644]) because the study used an insensitive species and strain \[although the NTP conducted low-dose, multigeneration reproduction studies with ethinyl estradiol (EE) and genistein in the SD rat and detected estrogenic effects ([@b39-ehp-117-1644])\] and in mice ([@b80-ehp-117-1644]) as "so flawed as to be useless" (Myers et al. 2009). Their specific criticisms and my responses are as follows:

Claim 1
-------

Myers et al. (2009) claimed that the positive control group used a very high E~2~ dosage (0.5 ppm in diet at \~ 0.080 mg/kg/day) in contrast to the mouse literature for E~2~ (e.g., [@b60-ehp-117-1644]; [@b90-ehp-117-1644]). They noted that the EFSA report ([@b16-ehp-117-1644]) failed to acknowledge that only a very high positive control dose was sufficient to elicit effects, and therefore the studies by Tyl and colleagues were insensitive to any estrogen and thus inappropriate for use in a study to examine low-dose estrogenic effects.

Tyl response
------------

The dietary positive control (0.5 ppm E~2~) was selected based on one-generation ([@b78-ehp-117-1644]) and two-generation ([@b79-ehp-117-1644]) CD-1 mouse studies using E~2~ doses of 0.001--50 ppm (8 mg/kg/day), with the most complete spectrum of effects seen at 0.5 ppm \[estrogenic effects were observed at 0.05 ppm (increased weanling uterine weight) with a NOAEL of \~ 1 μg/kg/day\]. Because E~2~ was dietary (animals were fed *ad libitum*, with ADME occurring as they fed), it took higher feed doses versus gavage or other routes to achieve the same test chemical response. Because almost all human BPA exposure is oral (during episodic eating/drinking), dosed feed is the most relevant exposure route.

No studies mentioned by Myers et al. (2009) investigated E~2~ after oral administration: [@b26-ehp-117-1644], [@b76-ehp-117-1644], and [@b90-ehp-117-1644] used DES; [@b58-ehp-117-1644], [@b59-ehp-117-1644] used oral EE; [@b76-ehp-117-1644] used estradiol benzoate by subcutaneous injection in rats, and [@b40-ehp-117-1644] used it by subcutaneous capsules in primates; [@b90-ehp-117-1644] used sub-cutaneously implanted Silastic E~2~ capsules; and [@b60-ehp-117-1644] used E~2~ (and BPA) in cell culture. We rejected EE (synthetic and greater oral bioavailability) and DES (multiple modes of action, no reproducible data that it is orally active at low doses) as positive controls.

In Table 9 of our paper ([@b78-ehp-117-1644]), we summarized key findings in rats and mice at the highest dietary concentrations producing viable offspring (2.5 ppm in rats; 0.5 ppm in mice), at doses of similar order of magnitude: mice, \~ 0.08--0.12 mg/kg/day; rats, \~ 0.17--0.2 mg/kg/day. Although there are differences in some end points, effects of exogenous estrogen in rats and mice are similar at similar doses. The concerns about our positive control and dietary concentration are unfounded.

Claim 2
-------

Myers et al. (2009) claimed that the "large" prostate weights suggest poor dissection technique, and that use of dissection, weight, and histopathology of the seminal vesicles plus coagulating glands (SVCG) together was "inappropriate."

Response
--------

Prostate weights (lobe or whole gland) in all mammals evaluated to date have increased with age as males mature sexually ([@b68-ehp-117-1644], for mice), as observed in our CD-1 mice. Mean control mouse prostate weights by lobe and age in our studies are presented in [Table 1](#t1-ehp-117-1644){ref-type="table"}. [Table 2](#t2-ehp-117-1644){ref-type="table"} shows mean mouse whole-prostate weights of mice of various ages reported by others.

My laboratory has extensive experience in weighing rat and mouse prostate glands at various ages. In the Hershberger inter-laboratory validation study, my laboratory had some of the most precise prostate weight data and robust treatment-related effects of the 17 participating laboratories (according to one senior OECD/U.S. EPA reviewer; personal communication). We performed power calculations on our rat and mouse prostate data versus data of [@b47-ehp-117-1644]. Because of larger sample sizes and smaller coefficients of variation, our data have greater power to detect small effects than the Nagel data (unpublished data). Examination of paraffin block faces and slides of the rat and mouse prostates in the our studies ([@b81-ehp-117-1644], [@b80-ehp-117-1644]) indicated no evidence of extraneous tissue/fat or excessive inflammation.

vom Saal's CF-1 offspring mice are routinely group housed by sex for several months beginning at weaning, and then singly housed for 1 month before necropsy. It is highly unlikely that 1 month of single housing compensated for months of group housing and its effect on male mouse sexual development; the dominant cage male develops large androgen-dependent accessory sex organs (ASOs), and subservient cage males have smaller ASOs ([@b6-ehp-117-1644]). vom Saal's CF-1 mice did not exhibit increased prostate weights with age, likely because of his postwean caging regimen. Adult control prostate weights in our reproductive toxicity studies with E~2~ ([@b78-ehp-117-1644], [@b79-ehp-117-1644]) and BPA ([@b80-ehp-117-1644]) ([Table 1](#t1-ehp-117-1644){ref-type="table"}) are well within the weight range of other published studies ([Table 2](#t2-ehp-117-1644){ref-type="table"}), and, as expected, our mouse prostate weights increased with increasing age.

We dissected, weighed, and examined the SVCG together to prevent tissue damage from necropsy separation of these intimately associated organs for histopathology, especially in mice.

Claim 3
-------

Myers et al. (2009) and vom Saal (at an FDA hearing on BPA safety assessment held 16 September 2008 in Washington, DC) stated that our animals must have had high incidence and severity of prostatitis to account for increased prostate weights.

Response
--------

For male mice exposed to E~2~ (0, 0.001, 0.005, 0.05, 0.15, and 0.5 ppm), histopathologic prostate examination by an independent pathologist indicated incidences of chronic inflammation (plus mononuclear cell infiltration): for F~0~ males, 0.0%, 16.7%, 0.0%, 8.3%, 9.1%, and 0.7%, respectively (*n* = 11--25/group); and for F~1~ males, 4.0%, 9.1%, 9.1%, 0.0%, 15.4%, and 0.0% (*n* = 10--25/group) ([@b79-ehp-117-1644]). For the mouse BPA study ([@b80-ehp-117-1644]), F~0~ male incidences were 6.7%, 2.2% (vehicle controls), 5.6%, 0.0%, 0.0%, 5.0%, 0.0%, 0.0% (BPA low to high doses: 0.018, 0.18, 1.8, 30, 300, and 3,500 ppm BPA, respectively), and 0.0% (positive control group; 0.5 ppm E~2~), *n* = 45--10/group; for F~1~ males, 3.6% and 0.0% (vehicle control), 0.0%, 4.2%, 10.0%, 0.0%, 0.0%, 7.7% (BPA low to high doses), and 3.3% (positive control), *n* = 20--56/group. Histopathologic characteristics of spontaneous prostate lesions in CD-1 mice ([@b12-ehp-117-1644]; [@b38-ehp-117-1644]; [@b72-ehp-117-1644]; [@b91-ehp-117-1644]) include the following:

-   Various degrees of inflammatory cell infiltration in interstitium

-   Neutrophilic infiltration and cellular debris accumulation in acini

-   Minimal reactive epithelial hyperplasia in involved acini ([@b73-ehp-117-1644]).

Our incidences in CD-1 mice match low incidences of prostatic inflammation (\~ 4--5%) in many mouse strains, with no treatment- or dose-related changes in incidence or severity.

In our BPA and E~2~ studies ([@b81-ehp-117-1644], [@b78-ehp-117-1644], [@b79-ehp-117-1644], [@b80-ehp-117-1644]), experienced prosectors (initially trained by veterinary pathologists) dissected reproductive tract organs, including prostates for adult and weanling males. Technicians were blind for doses (i.e., doses designated by Rx number and color code) to preclude inadvertent bias during all evaluations. Necropsy order was randomized such that prosectors dissected animals from all groups on all days, when possible.

Claim 4
-------

Myers et al. (2009) claimed that the use of Purina Certified Ground Rodent Chow No. 5002 was inappropriate because [@b75-ehp-117-1644] had reported that this diet was high in phytoestrogens and interfered with exogenous estrogen activity.

Response
--------

Most exploratory research studies, including those of vom Saal and colleagues, do not report phytoestrogen content of their diets, so it is difficult to compare diets used across laboratories. In our studies, mean phytoestrogen content of Purina 5002 feed batches was 192 ppm genistein, 177 ppm daidzein, and 45 ppm glycitein for mice ([@b80-ehp-117-1644]), and 128 ppm genistein, 131 ppm daidzein, and 50 ppm glycitein for rats ([@b81-ehp-117-1644]). These levels were relatively consistent across batches within studies and across time.

[@b75-ehp-117-1644] investigated acquisition of VP in CD-1 mice with various diets of low to high phytoestrogen content \[specifically daidzein and genistein (D&G)\] and concluded that higher dietary phytoestrogens accelerated VP.

Our mouse data indicated control F~1~ mean ages at VP were 27.0 ([@b79-ehp-117-1644]) and 29.4 ([@b78-ehp-117-1644]) days, with no phytoestrogen effect, because [@b75-ehp-117-1644] reported the following percentages of females acquiring VP at 22--30 days of age: for low D&G diets (0--20 μg/g), 3.6--86.6%; for midrange D&G diets (101--210 μg/g), 23.8--87.7%; and for high D&G diets (270--370 μg/g), 37.5--96.0%. Sensitivity of VP to exogenous estrogen was demonstrated in our E~2~ mouse studies, because F~1~ VP age was significantly accelerated to 21.3 days by 0.5 ppm ([@b78-ehp-117-1644]), to 21.0 days by 0.15 ppm, and to 20.7 days by 0.5 ppm ([@b79-ehp-117-1644]). In our mouse BPA study ([@b80-ehp-117-1644]), F~1~ VP was accelerated to 20.6 days in the 0.5-ppm E~2~ positive control group, compared with 25.5 days in controls. Our feed did not mask endocrine-sensitive responses to E~2~ (BPA doses administered were up to 7,000× higher).

Claim 5
-------

Myers et al. (2009) questioned our use of CD-1 Swiss mice from Charles River Laboratories (citing strain and source differences as the basis for differing results).

Response
--------

We purchased CD-1 mice from Charles River Laboratories (Raleigh, NC) for each study. We do not maintain in-house colonies because closed colonies (such as the CF-1 mouse colony maintained in vom Saal's laboratory since 1979) typically suffer from founder effects and/or genetic drift over time; vom Saal recently terminated his CF-1 mouse colony and began using CD-1 mice. Charles River International Gold Standard CD-1 mice are maintained by matings across their breeding facilities to preclude/minimize such effects.

Claim 6
-------

Myers et al. (2009) criticized our use of gross examinations, organ wet weights, tissue histopathology, and systemic and reproductive/developmental landmarks because they "were established procedures by the 1950s."

Response
--------

These parameters have been used for many years because they are sensitive, relevant, and validated. Newer end points have been added as they are validated (see above).

Claim 7
-------

Our reproductive toxicity study did not look at neurobehavioral end points.

Response
--------

Multigeneration studies are not designed to investigate neurobehavioral end points, although daily clinical observations in our studies ([@b81-ehp-117-1644], [@b80-ehp-117-1644]) gave no indications of neurotoxicity/neurobehavioral effects after BPA exposure (e.g., normal mating behaviors, nest building, nursing, pup retrieval, offspring landmark acquisition). [@b18-ehp-117-1644] included standard neurobehavioral end points and observed no effects in their two-generation, low-dose (0.2--200 μg/kg/day) BPA study. Specific U.S. EPA and OECD guidelines exist for adult and developmental neurotoxicity studies; definitive BPA investigations using these guidelines are planned or under way by the FDA and industry.

Claim 8
-------

Myers et al. (2009) said that the large number of animals overpowered the study and violated National Institutes of Health (NIH) and federal guidelines.

Response
--------

Guideline studies are performed not just to detect adverse effects but also to ascertain dose--response relationships and to provide some assurance of safety. These studies therefore require different statistical considerations and experimental power. OECD and U.S. EPA reproductive toxicity guidelines require ≥ 20 pregnant females at term per group. Because mice are not typically used in guideline-compliant reproductive toxicity studies, and we evaluated ordinal (as well as continuous) data, we used 28 mice/sex/group/generation. Studies with small groups and group sizes are of limited utility, and inappropriate statistical analyses, sometimes seen in exploratory studies (e.g., CERHR 2007), cannot determine whether there are treatment-related effects.

Larger numbers of animals per group provide more statistical power to detect intergroup differences. A dose--response trend suggests treatment-related effects, whereas no dose--response trend implies that effects might not be treatment related, so studies with only one or two dose groups are of limited utility.

Claim 9
-------

Myers et al. (2009) listed BPA low-dose effects not present in our GLP studies, including altered metabolism (e.g., [@b1-ehp-117-1644]), adiponectin secretion ([@b31-ehp-117-1644]), epigenetic programming causing increased susceptibility to prostate cancer ([@b28-ehp-117-1644]), changed gene expression and morphology of mammary glands ([@b15-ehp-117-1644]; [@b45-ehp-117-1644]; [@b70-ehp-117-1644]), neuroanatomic ([@b40-ehp-117-1644]) and neurobehavioral effects ([@b62-ehp-117-1644]), and altered offspring reproductive systems ([@b41-ehp-117-1644]; [@b49-ehp-117-1644]).

Response
--------

Low-dose BPA effects are from nonvalidated end points in exploratory studies, most after nonrelevant routes of administration: [@b70-ehp-117-1644], [@b41-ehp-117-1644], [@b45-ehp-117-1644], and [@b15-ehp-117-1644] used subcutaneous osmotic mini-pumps; [@b49-ehp-117-1644] and [@b28-ehp-117-1644] injected BPA; and [@b40-ehp-117-1644] implanted subcutaneous BPA capsules. Guideline-compliant studies must use appropriate routes and validated end points to detect adverse outcomes, for example, changes in survival, growth and/or development, body and/or organ weights, histopathology, and systemic and reproductive organ functions.

Claim 10
--------

Myers et al. (2009) argued that "NIH-funded research \[is\] subject to more stringent reviews than GLP." Their argument was that NIH applications require evidence of principal investigator competence, state-of-the-art methods, equipment, laboratory environment, publication of their findings in peer-reviewed journals, and are challenged by independent efforts to replicate their findings.

Response
--------

Risk-relevant guideline studies (including our BPA work) are not exploratory or "basic" research studies; they do not include unvalidated, cutting-edge techniques because they are required to use validated end points and parameters; they are welcomed, reviewed by experts, and published in highly respected journals.

A former *Nature* editor ([@b36-ehp-117-1644]) stated that "scientists understand that peer review per se provides only a minimal assurance of quality, and that the public conception of peer review as a stamp of authentication is far from the truth."

GLP-compliant studies require that all participants have current training files; have documentation showing that relevant SOPs are read, understood, and used; and are under independent quality assurance oversight. GLPs require that all data be included in the study report (and retained). Commonly, negative data are not published by many exploratory/basic research studies from universities or NGOs because they are not considered critical, whereas all data (positive/negative) are retained in guideline studies and are important in weight-of-evidence evaluations. Our mouse BPA study ([@b80-ehp-117-1644]) was also under formal oversight by noted reproductive toxicologists from the United Kingdom, Denmark, Germany, the Netherlands, Sweden, and the European Chemicals Bureau.

Current publication environments, which may distort science, including limited journals with high impact, limited journal space, bias toward exciting positive studies and certain authors, and so forth, concern the National Institute of Environmental Health Sciences and academia ([@b93-ehp-117-1644]).

There is no guarantee that basic research, federally (or other) funded and published in peer-reviewed journals, is reproducible or subject to more stringent review. The following are specific examples of nonreproducible data:

-   [@b65-ehp-117-1644] reported that gestational and lactational exposure of rats to xenoestrogens resulted in reduced testicular size and sperm production in adult offspring, but they rescinded their findings ([@b66-ehp-117-1644]) because neither they nor other laboratories could replicate their findings.

-   vom Saal's laboratory ([@b47-ehp-117-1644]) reported significantly enlarged prostates and significantly decreased epididymal sperm counts in F~1~ adult CF-1 offspring from maternal BPA oral gavage at 2 and 20 μg/kg/day on GDs 11--17 (the sperm findings were not confirmed at the NTP low-dose workshop, held at Research Triangle Park, NC, in 2002). Robust attempts to replicate vom Saal's prostate findings by [@b9-ehp-117-1644] and [@b5-ehp-117-1644] were unsuccessful (discussed above). Although not a direct comparison with work by [@b47-ehp-117-1644] in CF-1 mice, [@b29-ehp-117-1644] reported that EE gavage dosing of Long-Evans rat dams at 50 μg/kg/day from GD7 to post-natal day (PND) 18 reduced offspring body and androgen-dependent organ weights. However, BPA gavage dosing at 2, 20, or 200 μg/kg/day from GD7 to PND18 did not "significantly affect any male endpoint, including no effects on androgen-dependent organ weights or epididymal sperm count" ([@b29-ehp-117-1644]).

-   [@b32-ehp-117-1644] reported that BPA from cracked polycarbonate caging caused meiotic aneuploidy in genetically susceptible female mice, and dosing this strain with 20 μg/kg/day BPA for 7 days caused chromosome congression failure (disturbed metaphase chromosome alignment) during oocyte meiosis. A repeat of Hunt et al.'s study by [@b17-ehp-117-1644] found no BPA-induced aneuploidy. [@b56-ehp-117-1644] found no hyperploidy/polyploidy in oocytes/zygotes (but reported increased meta-phase II oocytes with prematurely separated chromatids after chronic BPA exposure).

-   [@b2-ehp-117-1644] reported that maternal intraperitoneal injection of vinclozolin (100 mg/kg/day) during early gonadal differentiation (GDs 8--15) in rats induced epigenetic alterations, which caused testicular histopathology, reduced sperm counts, and tumors in four offspring generations. Subsequent studies could not replicate these findings using intraperitoneal injection ([@b67-ehp-117-1644]; [@b71-ehp-117-1644]) or oral dosing ([@b64-ehp-117-1644]), and [@b3-ehp-117-1644] could not reproduce their original findings. [@b25-ehp-117-1644] gavaged pregnant SD rats with 100 mg/kg/day vinclozolin on GDs 8--15 or on GDs 13--17 during androgen-dependent sex differentiation (controls dosed on GDs 8--17). These authors found no effects on F~1~ male AGD, retained nipples/areolae, hypospadias, or fertility after GD 8--15 exposure, but they did find statistically and biologically significant effects on these parameters after GD 13--17 exposure, as expected (vinclozolin is an androgen-receptor antagonist). Normal testis histopathology and epididymal sperm counts in F~2~/F~3~ generations indicated that vinclozolin-related effects (from exposed F~0~ dams) were not transmitted to unexposed F~2~ and F~3~ offspring ([@b20-ehp-117-1644]).

There are also cases of data manipulation/fraud in NIH-supported, peer-reviewed research---more than 30 cases documented in the past 3 years according to the U.S. Public Health Service's [@b55-ehp-117-1644]. One example is the study of [@b4-ehp-117-1644], in which the authors reported huge synergistic effects of endocrine disruptors in the yeast estrogen assay *in vitro*. [@b43-ehp-117-1644] rescinded that paper because neither his laboratory nor others could replicate the findings. It was later determined that there was scientific misconduct and the original data were fabricated ([@b50-ehp-117-1644]).

[@b7-ehp-117-1644] stated that "a failure in replicability has blighted much of the low-dose BPA literature and it is essential to determine which, if any, of these findings are capable of independent replication." [@b35-ehp-117-1644] provocatively stated that "most published research findings are false," because the smaller studies have less power and therefore more bias, so the effects reported are less likely to be true.

Claim 11
--------

Myers et al. (2009) stated that GLP specifies nothing about the quality of the research design, the skills of the technicians, the sensitivity of the assays, or whether the methods employed are current or out of date. (All of the above are central issues in the view of a grant proposal by an NIH panel.)

Response
--------

GLP regulations are the only international legal framework that establishes quality standards and independent government-mandated inspections of facilities, study data, and staff training, with severe monetary/legal sanctions for noncompliance (see, e.g., [@b55-ehp-117-1644]). Many academic institutions are implementing GLPs up to full compliance, including quality assurance oversight. Unlike basic research, GLPs require documented ownership of data (regardless of collection media), verification of valid study design, protocol amendments for planned changes, protocol deviations for unplanned changes, retention of all data, and appropriate statistical analyses to ensure confidence in the study design, performance, and conclusions, providing assured sensitivity, reliability, and validity critical to formal risk assessment.

Designs of BPA guideline-compliant, reproductive toxicity studies (e.g., [@b18-ehp-117-1644]; [@b81-ehp-117-1644], [@b80-ehp-117-1644]) and other comprehensive studies (e.g., [@b5-ehp-117-1644]; [@b9-ehp-117-1644]; [@b29-ehp-117-1644]) include adverse end points that would result from effects, and in some cases include effects themselves, reported by the small, exploratory research studies. The striking conclusion is that none of these guideline-compliant or comprehensive studies, regardless of sponsorship, has been able to replicate effects reported for low-dose BPA on prostate or other male/female reproductive structures or functions. The novel, nonvalidated end points evaluated by small, basic research studies were not evaluated in the guideline-compliant studies, but any adverse consequences from them, as required for risk assessment, were sought and not found.

Weight of Evidence
==================

During weight-of-evidence evaluations, experts evaluate relevant articles and reports, with certain study designs and/or end points assigned greater/lesser weight. A number of BPA weight-of-evidence assessments (e.g., [@b16-ehp-117-1644]; [@b21-ehp-117-1644], [@b22-ehp-117-1644], [@b23-ehp-117-1644]; [@b24-ehp-117-1644]; [@b92-ehp-117-1644]) concur that studies do not support the hypothesis that low-dose oral BPA adversely affects human reproductive/developmental health.

Conclusions
===========

*Ad hominem* attacks are not appropriate or helpful in discussions of scientific and regulatory concerns. This controversy can be resolved only if the debate returns to a professional level ([@b63-ehp-117-1644]). To include new end points for hazard/risk assessment, we must validate the end points through rigorous regulatory acceptance processes, and replicate basic study effects using guideline studies. Success in validating relevant new end points, as well as performance of studies to follow early changes to subsequent adverse consequences *in vivo*, may provide "phenotypic anchoring" needed to use such end points for future hazard evaluations and risk assessments.

C[orrection]{.smallcaps}
========================

In [Table 1](#t1-ehp-117-1644){ref-type="table"} of the original manuscript published online, the age of F~1~ animals at termination was given as 16 weeks. The animals actually ranged in age from 16 to 19 weeks, based on time during the cohabitation period that mothers were inseminated and when pups were delivered \[Tyl RW. Ages of mice in the two-generation BPA study (Letter). Toxicol Sci (in press)\]. The table has been corrected here.

The BPA and E~2~ studies performed at RTI (a contract research organization) were funded by the American Plastics Council of the American Chemistry Council. The time to write this article was provided by the RTI Fellows Program (R.W.T. is a Distinguished Fellow).

I thank RTI International's Fellows Program for time to write this article; the senior and technical staff at RTI for their extraordinary dedication and expertise on the bisphenol A (BPA) and 17β-estradiol (E~2~) studies discussed; C.A. Winkie for her patient typing and retyping of the manuscript; and the *Environmental Health Perspective* reviewers.

###### 

CD-1 (Swiss) mouse control male prostate weights (mean ± SD).

  Reference                                                         Age (weeks)          Terminal body weight (g)   Mean absolute prostate weight (mg)                
  ----------------------------------------------------------------- -------------------- -------------------------- ------------------------------------ ------------ ------------
  [@b78-ehp-117-1644][a](#tfn2-ehp-117-1644){ref-type="table-fn"}   12--13 (F~0~)        41.19 ± 1.08               43.2 ± 4.7                           ND           ND
  [@b79-ehp-117-1644][b](#tfn3-ehp-117-1644){ref-type="table-fn"}   19 (F~0~)            36.66 ± 0.77               82.0 ± 6.0                           39.0 ± 4.0   42.0 ± 4.0
                                                                    16--19 (F~1~)        37.37 ± 0.71               58.0 ± 3.0                           25.0 ± 2.0   34.0 ± 2.0
                                                                    18 (F~1~ retained)   38.89 ± 1.12               58.0 ± 5.0                           24.0 ± 2.0   34.0 ± 4.0
  [@b80-ehp-117-1644][c](#tfn4-ehp-117-1644){ref-type="table-fn"}   19 (F~0~)            39.53 ± 0.50               72.5 ± 3.6                           34.8 ± 2.6   37.7 ± 1.7
                                                                    16--19 (F~1~)        38.89 ± 0.53               71.9 ± 2.2                           26.5 ± 1.4   45.8 ± 1.7
                                                                    18 (F~1~ retained)   40.46 ± 0.67               74.4 ± 2.9                           28.8 ± 2.4   45.6 ± 2.2

ND, not determined.

Ten F~0~ males in control group.

Twenty-five males in control group/generation.

Fifty-six males in combined control groups/generation.

###### 

Prostate weights in adult male control mice.

  Reference                                                         Mouse strain   Age (weeks)   Whole prostate weight (mg)
  ----------------------------------------------------------------- -------------- ------------- ----------------------------
  [@b5-ehp-117-1644][a](#tfn5-ehp-117-1644){ref-type="table-fn"}    CF-1           25--26        \~ 50
  [@b9-ehp-117-1644][a](#tfn5-ehp-117-1644){ref-type="table-fn"}    CF-1           13            \~ 40
  [@b26-ehp-117-1644]                                               CD-1           8.5--9        \~ 40
  [@b27-ehp-117-1644]                                               CD-1           16--17        \~ 45.9
  [@b44-ehp-117-1644]                                               CD-1           23            58.3
  [@b47-ehp-117-1644][b](#tfn6-ehp-117-1644){ref-type="table-fn"}   CF-1           27--28        41
  [@b51-ehp-117-1644][b](#tfn6-ehp-117-1644){ref-type="table-fn"}   CF-1           14--15        49--59
  [@b61-ehp-117-1644]                                               CD-1           13            \~ 42
  [@b74-ehp-117-1644]                                               CD-1           8.5--9        16--34
  [@b89-ehp-117-1644][b](#tfn6-ehp-117-1644){ref-type="table-fn"}   CF-1           15            50
  [@b90-ehp-117-1644][b](#tfn6-ehp-117-1644){ref-type="table-fn"}   CF-1           34--35        42
  [@b89-ehp-117-1644][b](#tfn6-ehp-117-1644){ref-type="table-fn"}   CF-1           77            105

[@b9-ehp-117-1644] and [@b5-ehp-117-1644] used CF-1 mice purchased from commercial suppliers.

The closed CF-1 mouse colony (maintained at the University of Missouri--Columbia since 1979) has since been terminated by vom Saal.
